Search

Joseph R Naemura

from Bellevue, WA
Age ~71
Get Report
Also known as:
Joe R Naemura, Janie M Naemura, Jeffrey Naemura, H Okawa
Phone and address:
2627 127Th Ave NE, Bellevue, WA 98005
(425) 885-7492
Related to:
Eric HoodWilliam H Naemura, 66David NaemuraSharon Naemura, 81
Connected to:
Sopee Naenphan, 37Alan C Naeole, 66June U Naeole, 54Erna E Naert, 60Jennifer M Naert, 48Vincent D Naert, 61Joshua A Naes, 42Richard N Naes, 68Ann M Naess, 94Erica M Naess, 40

Joseph Naemura Phones & Addresses

  • 2627 127Th Ave NE, Bellevue, WA 98005 (425) 885-7492
  • Newbury Park, CA
  • San Diego, CA
  • Portland, OR
  • 2627 127Th Ave NE, Bellevue, WA 98005

Publications

Us Patents

Methods For Protecting Allogeneic Islet Transplant Using Soluble Ctla4 Mutant Molecules

View page
US Patent:
7304033, Dec 4, 2007
Filed:
May 23, 2002
Appl. No.:
10/155514
Inventors:
Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16
C07K 14/00
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.

Methods Of Treatment Using Ctla4 Mutant Molecules

View page
US Patent:
7439230, Oct 21, 2008
Filed:
Nov 3, 2004
Appl. No.:
10/980742
Inventors:
Robert J. Peach - San Diego CA, US
Joseph R. Naemura - Bellevue WA, US
Peter S. Linsley - Seattle WA, US
Jurgen Bajorath - Lynwood WA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16
A61K 39/395
C07K 14/00
C07K 14/725
C07K 16/46
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Methods For Treating Immune System Diseases Using A Soluble Ctla4 Molecule

View page
US Patent:
7455835, Nov 25, 2008
Filed:
Jul 2, 2001
Appl. No.:
09/898195
Inventors:
Robert Cohen - Newtown PA, US
Robert James Peach - San Diego CA, US
David Hagerty - Cardiff by the Sea CA, US
Suzette Carr - Hopewell NJ, US
Jean-Claude Becker - Princeton NJ, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16
C07K 14/00
C07K 14/705
US Classification:
4241341, 514 12, 530350, 5303873
Abstract:
The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.

Methods Of Treatment Using Ctla4 Mutant Molecules

View page
US Patent:
7700556, Apr 20, 2010
Filed:
Mar 20, 2007
Appl. No.:
11/725762
Inventors:
Robert James Peach - San Diego CA, US
Joseph Naemura - Bellevue WA, US
Peter S. Linsley - Seattle WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16
US Classification:
514 12, 4241341
Abstract:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Methods For Protecting Allogeneic Islet Transplant Using Soluble Ctla4 Mutant Molecules

View page
US Patent:
7829534, Nov 9, 2010
Filed:
Oct 29, 2007
Appl. No.:
11/978701
Inventors:
Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16
C07K 14/705
C07K 16/46
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.

Soluble Ctla4 Mutant Molecules And Uses Thereof

View page
US Patent:
20020182211, Dec 5, 2002
Filed:
May 23, 2001
Appl. No.:
09/865321
Inventors:
Robert Peach - San Diego CA, US
Joseph Naemura - Bellevue WA, US
Peter Linsley - Seattle WA, US
Jurgen Bajorath - Lynwood WA, US
International Classification:
A61K039/395
C07H021/04
C07K016/28
C12N005/06
C12P021/02
US Classification:
424/143100, 530/388220, 435/069100, 435/326000, 435/320100, 536/023530
Abstract:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Soluble Ctla4 Mutant Molecules And Uses Thereof

View page
US Patent:
20030035816, Feb 20, 2003
Filed:
Jan 28, 1998
Appl. No.:
09/014761
Inventors:
ROBERT JAMES PEACH - CHURCHVILLE PA, US
JOSEPH NAEMURA - BELLEVUE WA, US
PETER S. LINSLEY - SEATTLE WA, US
JURGEN BAJORATH - LYNWOOD WA, US
International Classification:
C07H021/04
C12P021/06
A61K045/00
A61K047/00
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
C12N005/00
C12N005/02
C07K001/00
C07K014/00
C07K017/00
US Classification:
424/278100, 530/351000, 536/023500, 435/069100, 435/320100, 435/325000
Abstract:
The invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD86 antigen than wildtype CTLA4.

Soluble Ctla4 Mutant Molecules And Uses Thereof

View page
US Patent:
20030219863, Nov 27, 2003
Filed:
Jan 2, 2003
Appl. No.:
10/336384
Inventors:
Robert Peach - Southampton PA, US
Joseph Naemura - Bellevue WA, US
Peter Linsley - Seattle WA, US
Jurgen Bajorath - Lynnwood WA, US
Assignee:
Bristol-Myers Squibb Company
International Classification:
A61K038/17
C07H021/04
C12P021/02
C12N005/06
C07K014/74
US Classification:
435/069100, 435/320100, 435/325000, 514/012000, 530/350000, 536/023500
Abstract:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wildtype CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 and M97-G107 are mutated. The mutant molecules of the invention also include a second amino acid sequence which increases the solubility of the mutant molecule.
Control profile
Joseph R Naemura from Bellevue, WA, age ~71 Get Report